Skip to main content
. 2024 Sep 2;44(11):1231–1260. doi: 10.1002/cac2.12607

FIGURE 6.

FIGURE 6

shSRSF10 or 1C8 inhibition impeded tumor progression and enhances immunotherapy response in HCC. (A) Workflow of the subcutaneous HCC tumor treated with control or PD‐1 mAbs. (B) Tumor growth curves of subcutaneous HCC tumor treated with control or PD‐1 mAbs (n = 6). (C) Representative image of a Hepa1‐6 cell‐derived tumor harvested from a C57BL/6 mouse on day 14 (n = 6). (D) Summary of weight data from Hepa1‐6 tumors collected after the mice were euthanized (n = 6). (E) Percentages of tumor‐infiltrating F4/80+ macrophages, CD206+ macrophages, CD8+ T cells IFN‐γ+ CD8+ T cells from control and shSrsf10 HCC tumor (n = 6). (F) Workflow of the subcutaneous HCC tumor treated with DMSO or 1C8. (G) Tumor growth curves of subcutaneous HCC tumor treated with DMSO or 1C8 (n = 6). (H) Representative image of a Hepa1‐6 cell‐derived tumor harvested from a C57BL/6 mouse on day 15 (n = 6). (I) Summary of weight data from Hepa1‐6 tumors collected after the mice were euthanized (n = 6). (J Percentages of tumor‐infiltrating F4/80+ macrophages, CD206+ macrophages, CD8+ T cells, IFN‐γ+ CD8+ T cells from DMSO and 1C8 treated HCC tumor (n = 6). (K) Workflow of the spontaneous HCC tumor treated with PD‐1 mAbs and/or 1C8. (L) Representative image of spontaneous HCC liver harvested from a C57BL/6 mouse on day 21 (n = 6). (M) Summary of liver weight data from spontaneous tumor collected after the mice were euthanized (n = 6). (N) Kaplan–Meier survival curves for spontaneous tumor mice (n = 6). (O) Percentages of tumor‐infiltrating F4/80+ macrophages, CD206+ macrophages, CD8+ T cells IFN‐γ+ CD8+ T cells from spontaneous HCC tumor (n = 6). Two‐tailed unpaired Student's t test (B, D‐E, G, I‐J, M, O); Log Rank test(N); ns, not significant; * P < 0.05, ** P < 0.01, *** P < 0.001. Abbreviations: PD‐1, programmed cell death 1; DMSO, Dimethyl Sulfoxide; Ctnnb1, catenin beta 1; Tp53, tumor protein p53; SRSF10, serine and arginine rich splicing factor 10; HCC, Hepatocellular carcinoma; mAbs, monoclonal antibodies; IFN‐γ, Interferon gamma.